Group B Streptococcus alpha-like protein N-terminal domain fusion protein (GBS-NN2) (GBS-NN2)

The GBS-NN2 fusion protein is a component of a next-generation vaccine in clinical development for protection against Group B Streptococcus infections. GBS-NN2 comprises the N-terminal domains of Alp1 and Alp2/3, surface-exposed proteins on GBS that are highly immunogenic and prevalent across clinical isolates. Combined with GBS-NN (RibN + AlpCN), this approach is expected to elicit broadly protective antibody responses in vaccinated individuals, including maternal transfer of protective immunity to newborns. The protein is not a classic receptor, enzyme, or ion channel, but a rationally designed antigen based on structural and epidemiological knowledge of GBS surface proteins. If further structure-function or drug interaction details are required, these would likely be available from specialized biochemical or immunological studies, but current literature and vaccine development data robustly support the above profile.

Other names

Group B Streptococcus NN2 fusion proteinGBS-AlpN fusion protein (when discussed with its companion GBS-NN)Alp1N–Alp2/3N fusion protein

Induction of pathogen-specific IgG and IgA antibodies Antibody-mediated opsonophagocytic killing Blockade of bacterial adherence and invasion